Elranatamab

Summary

Elranatamab (CHEMBL4297809) is an approved antibody (ATC L01FX32); indicated across 3 conditions including plasma cell myeloma and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FX32
• Indications: 3 conditions
• Clinical trials: 47

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297809
Name	Elranatamab
Type	Antibody
Max phase	4
ATC	L01FX32

Also known as: Elranatamab, Elranatamab-bcmm, Elrexfio, Pf-06863135, PF-06863135, RN-613, RN613, ELRANATAMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378
neoplasm	4	MONDO:0005070	EFO:0000616
smoldering plasma cell myeloma	2	MONDO:0005235	EFO:0003073

Clinical trials

Total trials: 47.

Phase distribution

Phase	Trials
PHASE2	19
Not specified	9
PHASE1	8
PHASE3	5
PHASE1/PHASE2	5
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06057402	PHASE4	RECRUITING	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT05020236	PHASE3	RECRUITING	A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05317416	PHASE3	ACTIVE_NOT_RECRUITING	Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05623020	PHASE3	RECRUITING	A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT06152575	PHASE3	RECRUITING	MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06918002	PHASE3	RECRUITING	Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT04068597	PHASE1/PHASE2	RECRUITING	Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04649359	PHASE2	ACTIVE_NOT_RECRUITING	MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
NCT06015542	PHASE2	RECRUITING	Self-administration of Subcutaneous Elranatamab in the Patients’ Homes.
NCT06106945	PHASE1/PHASE2	RECRUITING	AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06138275	PHASE2	RECRUITING	Elranatamab in R/R Multiple Myeloma
NCT06183489	PHASE2	RECRUITING	Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
NCT06207799	PHASE2	RECRUITING	Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
NCT06282978	PHASE2	ACTIVE_NOT_RECRUITING	Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
NCT06421675	PHASE2	RECRUITING	Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06569147	PHASE1/PHASE2	RECRUITING	Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
NCT06645678	PHASE1/PHASE2	RECRUITING	Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NCT06711705	PHASE2	RECRUITING	Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06832865	PHASE2	RECRUITING	ELISA in Relapsed/Refractory MM
NCT06931704	PHASE2	NOT_YET_RECRUITING	Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
NCT06947083	PHASE2	RECRUITING	Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
NCT06974786	PHASE2	RECRUITING	Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06988488	PHASE1/PHASE2	RECRUITING	A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06997081	PHASE2	RECRUITING	ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
NCT07247097	PHASE2	NOT_YET_RECRUITING	ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
NCT07382739	PHASE2	RECRUITING	A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) PRIME-EMD-PMD
NCT07454382	PHASE2	RECRUITING	A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
NCT05014412	PHASE2	COMPLETED	A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
NCT05090566	PHASE2	TERMINATED	MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05228470	PHASE2	COMPLETED	A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
NCT05675449	PHASE1	ACTIVE_NOT_RECRUITING	A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05927571	PHASE1	RECRUITING	A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT06121843	PHASE1	RECRUITING	A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06215118	PHASE1	RECRUITING	A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06799026	PHASE1	RECRUITING	A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
NCT07280013	PHASE1	RECRUITING	A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT03269136	PHASE1	COMPLETED	PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
NCT04798586	PHASE1	COMPLETED	MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
NCT06581848	Not specified	ACTIVE_NOT_RECRUITING	Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
NCT06855121	Not specified	RECRUITING	The Norwegian Immunotherapy in Multiple Myeloma Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).